Pluristem Therapeutics And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy To Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation to fund the research Constitutes a 3rd potential hematologic indication for PLX-R18 HAIFA, Israel, Dec. 27, 2016 — Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced that it will collaborate with the New York Blood Center on preclinical studies of its Placental eXpanded -R18 cells to enhance the efficacy of umbilical cord blood transplantation.